Keymed Biosciences Inc. (HKG:2162)

Market Cap	25.42B +37.4%
Revenue (ttm)	963.56M -4.3%
Net Income	893.16M
EPS	3.13
Shares Out	294.60M
PE Ratio	27.64
Forward PE	52.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,255,200
Open	87.55
Previous Close	86.60
Day's Range	85.30 - 89.45
52-Week Range	44.66 - 89.75
Beta	-0.16
Analysts	Strong Buy
Price Target	104.43 (+21.01%)
Est. Earnings	Nov 20, 2026

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,768
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2162

Financial Performance

In 2025, Keymed Biosciences's revenue was 716.31 million, an increase of 67.31% compared to the previous year's 428.12 million. Losses were -522.64 million, 1.44% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 15 analysts, the average rating for 2162 stock is "Strong Buy." The 12-month stock price target is $104.43, which is an increase of 21.01% from the latest price.

Price Target

$104.43

(21.01% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 21, 2026

Data Sources Report a data error